Sulfated polysaccharide compound and the preparation and use thereof

Abstract

The present invention relates to a sulfated polysaccharide compound and the preparation and use thereof, and in particular to a narrow distribution low molecular weight, highly sulfated pentosan (in this instance a xylan) referred to as glucuronoxylan sulfate (GXS). The invention has been developed primarily for use in the treatment of various clinical conditions. However, it will be appreciated that the invention is not restricted this particular field of use.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a sulfated polysaccharide compound and the preparation and use thereof, and in particular to a narrow distribution low molecular weight, highly sulfated pentosan (in this instance a xylan) referred to as glucuronoxylan sulfate (GXS).[0002]The invention has been developed primarily for use in the treatment of various clinical conditions. However, it will be appreciated that the invention is not restricted this particular field of use.COPYRIGHT NOTICE[0003]This document is subject to copyright. The reproduction, communication and distribution of this document is not permitted without prior consent from the copyright owner, other than as permitted under section 226 of the Patents Act 1990.Problems of the Prior ArtUnder-Sulfation[0004]Highly sulfated (sulfate esters) glycans and glycosaminoglycans form a significant therapeutic class of pharmaceuticals in human and veterinary medicine. Sulfate esters demonstrate a broad range ...

AI Technical Summary

Problems solved by technology

Their derivation and synthesis have long proved to be very challenging, with production outcomes being highly variable.

This has translated to inconsistent clinical outcomes.

However, in practice, it has proved difficult to achieve a consistently high level of sulfation at consistent positions along the chain and in a low molecular weight range.

Also, the degree of sulfation within known PPS formulations can vary widely, which can also lead to variability in clinical efficacy.

Indeed to date, there is also no substantiation in the prior art of 19% sulfation for PPS, let alone higher degrees of sulfation.

Differences in the manufacturing process (especially during hydrolysis and sulfation) can result with molecular differences of the PPS molecule, such as the degree of sulfation and the position of sulfate groups on the glycan chain.

This is well known in relation to heparin but to date this knowledge has not been adequately applied to the PPS molecule(s).

However, like heparin, the effects of unfractionated natural PPS can be difficult to predict.

However, in practice, it has been difficult to achieve consistency of the heterogeneous mixture of carbohydrates that make up PPS during commercial production.

This is because it has been difficult to achieve a consistent average molecular weight, consistently low molecular weight and steady but high level of sulfation.

Images